Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Sep 2018.
- 07 Aug 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2017.
- 15 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov